Background: New-onset diabetes after transplantation (NODAT) is a serious complication following liver transplantation (LT). The present study aimed to investigate the incidence of and risk factors for NODAT using the Korean Organ Transplantation Registry (KOTRY) database.

Methods: Patients with history of pediatric transplantation (age ≤18 years), re-transplantation, multi-organ transplantation, or pre-existing diabetes mellitus were excluded. A total of 1,919 non-diabetic adult patients who underwent a primary LT between May 2014 and December 2017 were included. Risk factors were identified using Cox regression analysis.

Results: NODAT occurred in 19.7% (n=377) of adult liver transplant recipients. Multivariate analysis showed steroid use, increased age, and high body mass index (BMI) in recipients, and implantation of a left-side liver graft was closely associated with NODAT in adult LT. In living donor liver transplant (LDLT) patients (n=1,473), open donor hepatectomy in the living donors, steroid use, small for size liver graft (graft to recipient weight ratio ≤0.8), increased age, and high BMI in the recipient were predictive factors for NODAT. The use of antimetabolite and basiliximab induction reduced the incidence of NODAT in adult LT and in adult LDLT.

Conclusions: Basiliximab induction, early steroid withdrawal, and antimetabolite therapy may prevent NODAT after adult LT. High BMI or advanced age in liver recipients, open donor hepatectomy in living donors, and small size liver graft can predict the occurrence of NODAT after adult LT or LDLT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423540PMC
http://dx.doi.org/10.21037/hbsn.2019.10.29DOI Listing

Publication Analysis

Top Keywords

nodat adult
16
liver graft
12
new-onset diabetes
8
adult
8
liver
8
adult liver
8
liver transplantation
8
korean organ
8
organ transplantation
8
transplantation registry
8

Similar Publications

Background: Sodium-glucose co-tranporter-2 inhibitors have been shown to be safe and effective in patients with type 2 diabetes for improving glycemia. Furthermore large, randomized control trials have shown cardiovascular and renal benefits. However, limited safety and efficacy data is available in kidney transplant patients with diabetes.

View Article and Find Full Text PDF
Article Synopsis
  • * Nine participants (mostly women with median age 57) were monitored over 30 days using the Dexcom G6 CGM system after kidney transplantation, revealing that time in the healthy glucose range was above 70%.
  • * While the CGM use didn't change HbA1c levels or overall quality of life perception, it did enhance health quality perception for participants, indicating a potential benefit that warrants further research.
View Article and Find Full Text PDF

New onset diabetic ketoacidosis in a renal transplant recipient.

Am J Med Sci

August 2024

Professor and Chief Division of Nephrology, Medical College of Georgia at Augusta University, Augusta, Georgia. Electronic address:

Post-transplant diabetes mellitus (PTDM) is a well-known solid organ transplant complication, which can be related to immunosuppressants, particularly tacrolimus. We report an unusual presentation of PTDM with diabetic ketoacidosis (DKA). This is unique as PTDM typically resembles Type 2 DM, whereas DKA is associated with Type 1 DM and has rarely been reported as a complication of tacrolimus.

View Article and Find Full Text PDF

Clinical characteristics of new-onset diabetes after liver transplantation and outcomes.

Ann Gastroenterol Surg

May 2024

Division of Transplant and Hepatobiliary Surgery Henry Ford Health System Detroit Michigan USA.

Background: We aimed to identify the characteristics of new-onset diabetes after liver transplantation (LT) (NODAT) and investigate its impacts on post-transplant outcomes.

Methods: Adult LT patients between 2014 and 2020 who used tacrolimus as initial immunosuppression and survived 3 months at least were evaluated. Patients who developed NODAT within 3 months after LT were classified as NODAT group.

View Article and Find Full Text PDF

Purpose: New-onset diabetes after transplantation (NODAT) is a frequent metabolic complication associated with podocyte damage and renal allograft dysfunction. Thus, Wilm's tumor-1 (WT-1) protein, as a podocyte marker, holds promise as an option to evaluate renal allograft dysfunction in NODAT. Therefore, the study aimed to investigate urinary WT-1 levels in NODAT patients during the first year after kidney transplantation (KTx).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!